-
Austin-based Saturn V Capital Administration acquired 886,332 shares of Pharvaris within the third quarter.
-
Saturn V now holds 886,332 PHVS shares valued at $22.1 million.
-
PHVS is a brand new addition, accounting for 4.9% of 13F AUM, which locations it exterior the fund’s high 5 holdings.
-
These 10 shares might mint the subsequent wave of millionaires ›
On November 14, Austin-based Saturn V Capital Administration disclosed a brand new place in Pharvaris N.V. (PHVS), buying 886,332 shares valued at roughly $22.1 million through the third quarter.
Based on a Securities and Change Fee (SEC) submitting dated November 14, Saturn V Capital Administration initiated a brand new place in Pharvaris N.V. (PHVS). The fund reported holding 886,332 shares valued at $22.1 million at quarter-end. This addition expanded its complete reportable U.S. fairness positions to 17 as of September 30, bringing complete fund AUM to $456 million.
The PHVS stake represents about 4.9% of Saturn V Capital Administration LP’s 13F AUM.
Prime holdings after this submitting:
-
NASDAQ: ABVX: $68 million (14.9% of AUM)
-
NASDAQ: AMLX: $62.6 million (13.7% of AUM)
-
NASDAQ: JAZZ: $39.6 million (8.7% of AUM)
-
NASDAQ: DYN: $33.8 million (7.4% of AUM)
-
NASDAQ: COGT: $29.1 million (6.4% of AUM)
As of Monday, shares of Pharvaris N.V. have been priced at $25.35, up 33% over the previous yr and outperforming the S&P 500, which is up 12% in the identical interval.
|
Metric
|
Worth
|
|
Worth (as of market shut Monday)
|
$25.35
|
|
Market Capitalization
|
$1.6 billion
|
|
Internet Revenue (TTM)
|
($163.7 million)
|
|
1-12 months Worth Change
|
33%
|
-
Pharvaris focuses on the event of oral therapies for hereditary angioedema (HAE), together with PHA121 (Part II), PHVS416 (on-demand mushy capsule, Part II), and PHVS719 (prophylactic extended-release pill, Part I).
-
The corporate operates as a clinical-stage biopharmaceutical firm, producing worth by way of analysis and improvement with the intention of future commercialization of proprietary drug candidates for uncommon ailments.
-
It targets sufferers affected by hereditary angioedema, addressing each acute and prophylactic therapy wants in uncommon illness markets throughout Europe and the USA.
Pharvaris N.V. is a clinical-stage biotechnology firm specializing within the improvement of novel oral therapies for hereditary angioedema (HAE), a uncommon and critical genetic dysfunction. The corporate leverages its experience in small molecule drug design to advance a pipeline of differentiated candidates focusing on bradykinin B2-receptor pathways. Pharvaris goals to handle vital unmet medical wants in uncommon illness markets, positioning itself for long-term progress as its lead belongings progress by way of scientific improvement.
Pharvaris has three pivotal applications underway, and with €329 million in money readily available as of September 30, the corporate believes it’s financed into the primary half of 2027 — effectively previous its main information readouts. That visibility, mixed with differentiated oral candidates in each acute and prophylactic hereditary angioedema (HAE), helps clarify why the fund carved out one in every of its bigger new positions regardless of shares nonetheless sitting roughly one-third beneath their post-IPO peak.
Saturn V’s stake represents 4.9% of its 13F belongings, per the fund’s biotech-heavy profile and urge for food for high-conviction scientific threat. For shareholders, the RAPIDe-3 Part 3 outcomes launched final week confirmed constructive topline information, together with a median time to onset of symptom aid of 1.3 hours. Nonetheless, the corporate stays pre-revenue and continues to put up widening R&D prices — €29.8 million final quarter versus €25.8 million a yr earlier — underscoring each the chance and uncertainty forward.
For long-term traders, the takeaway is obvious: This can be a pipeline-driven story the place significant worth creation hinges on late-stage scientific success, however the steadiness sheet offers the time wanted to get there.
13F reportable AUM: Belongings underneath administration reported by institutional funding managers in quarterly SEC Type 13F filings.
Internet place change: The distinction within the worth of a fund’s holding in a safety after a transaction, reflecting new investments or gross sales.
Medical-stage biopharmaceutical firm: An organization growing medicine which are nonetheless being examined in human scientific trials, not but accredited on the market.
Hereditary angioedema (HAE): A uncommon genetic dysfunction inflicting recurrent swelling in numerous elements of the physique.
Prophylactic: Supposed to forestall illness or a medical situation, slightly than deal with it after onset.
On-demand remedy: Medicine taken solely when signs happen, slightly than on a daily schedule.
Bradykinin B2-receptor: A protein concerned in irritation and swelling, focused by sure medicine for HAE.
Pipeline: The portfolio of drug candidates an organization is growing, typically at numerous levels of scientific testing.
Belongings underneath administration (AUM): The entire market worth of investments managed by a fund or funding agency.
TTM: The 12-month interval ending with the newest quarterly report.
Quarter-end: The final day of a fiscal quarter, typically used as a reference level for monetary reporting.
Market outperform: When an funding’s return exceeds the efficiency of a benchmark index, such because the S&P 500.
Ever really feel such as you missed the boat in shopping for probably the most profitable shares? Then you definitely’ll need to hear this.
On uncommon events, our skilled staff of analysts points a “Double Down” inventory advice for firms that they assume are about to pop. Should you’re nervous you’ve already missed your probability to speculate, now could be the most effective time to purchase earlier than it’s too late. And the numbers communicate for themselves:
-
Nvidia: if you happen to invested $1,000 after we doubled down in 2009, you’d have $473,121!*
-
Apple: if you happen to invested $1,000 after we doubled down in 2008, you’d have $53,035!*
-
Netflix: if you happen to invested $1,000 after we doubled down in 2004, you’d have $540,587!*
Proper now, we’re issuing “Double Down” alerts for 3 unimaginable firms, out there whenever you be a part of Inventory Advisor, and there will not be one other probability like this anytime quickly.
See the three shares »
*Inventory Advisor returns as of December 8, 2025
Jonathan Ponciano has no place in any of the shares talked about. The Motley Idiot has no place in any of the shares talked about. The Motley Idiot has a disclosure coverage.
This Biotech Fund Simply Made a $22 Million Wager on Pharvaris Inventory — Is It a Purchase? was initially printed by The Motley Idiot
